Barclays Initiates Coverage of Sutro Biopharma (STRO) with Overweight Recommendation

Barclays initiated coverage of Sutro Biopharma (NasdaqGM: STRO) with an Overweight rating on May 28, 2026. The analyst price forecast implies 14.40% upside from current levels. The note is supportive for sentiment but is likely to have limited standalone market impact absent new operating updates.

Analysis

Barclays initiated coverage of Sutro Biopharma (NasdaqGM: STRO) with an Overweight rating on May 28, 2026. The analyst price forecast implies 14.40% upside from current levels. The note is supportive for sentiment but is likely to have limited standalone market impact absent new operating updates.